October 2018, Volume 8, Issue 5

How are the transplants becoming safer - good news for patients who seek cure from thalassemia

It has been three years since the time Sankalp started the program for thalassemia cure. We started our bone marrow transplantations for patients who had a matched related donor only. Even in this selected group of patient, recent data shows that the team has achieved 95.5% disease free survival and 98.3% overall survival last year, building upon the success of previous years. Specially in the matched sibling context, the team improved disease free survival from 89.1% across the years to 98.3% for last year alone.